triple acting glp 1 LY3437943, a novel glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept From Obesity to Metabolic Health:

Watch to see how it works

Accessed July 10, 2024.

Treatment duration was estimated using prescription span, and adherence could not be confirmed

The Cornell team notes that GLP-1s could complement existing nutritional interventions but cautions that their broader public health relevance ultimately depends on sustained adherence. For investors, the practical question is positioning

Active GLP-1 was measured by an active GLP-1 ELISA kit as per manufacturer instructions [29] ( n = number of individual experiments performed in triplicates)

This is associated with glucagon suppression and delayed gastric emptying, which may help moderate glucose absorption and reduce postprandial blood sugar spikes